Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers
- PMID: 1534211
- PMCID: PMC189237
- DOI: 10.1128/AAC.36.1.115
Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers
Abstract
Teicoplanin pharmacokinetics were evaluated after multiple-dose intravenous administration to healthy male volunteers by using a randomized, double-blind, parallel design. Doses of 3, 12, or 30 mg of teicoplanin per kg of body weight were administered every 24 h for 14 days as 60-min constant-rate intravenous infusions. Blood and urine samples were collected over 21 days and analyzed by a microbiological assay. Twenty-three subjects were included in the pharmacokinetic analysis. The median pharmacokinetic parameters upon multiple-dose intravenous administration of 3, 12, and 30 mg/kg included steady-state volumes of distribution of 0.94, 0.77, and 0.68 liter/kg; total clearances of 11.9, 12.0, and 13.2 ml/h/kg; and terminal disposition half-lives of 143, 166, and 96 h, respectively. Renal clearance accounted for approximately 95% of total clearance. No dose-related differences existed for teicoplanin total or renal clearance. The steady-state volume of distribution decreased significantly with increasing doses. As a result of the decrease in the volume of distribution, the terminal disposition half-life at 30 mg/kg was significantly decreased. However, the decreases in the volume of distribution and terminal disposition half-life are of limited clinical importance, since steady-state trough concentrations in serum increase in proportion to dose. Combined results of all multiple-dose studies with similar durations of sample collection indicate no dose-related differences for any pharmacokinetic parameters from 3 to 12 mg/kg. As observed in the present study, no dose-related differences exist for teicoplanin total and renal clearances from 3 to 30 mg/kg. However, at 30 mg/kg, a significant decrease in the steady-state volume of distribution is observed. As a consequence of the reduction in the volume of distribution at 30 mg/kg with no change in clearance, the terminal disposition half-life is decreased.
Similar articles
-
Clinical pharmacokinetics of teicoplanin.Clin Pharmacokinet. 2000 Sep;39(3):167-83. doi: 10.2165/00003088-200039030-00001. Clin Pharmacokinet. 2000. PMID: 11020133 Review.
-
Pharmacokinetics of teicoplanin upon multiple dose intravenous administration to normal healthy male volunteers.Biopharm Drug Dispos. 1992 Apr;13(3):213-20. doi: 10.1002/bdd.2510130307. Biopharm Drug Dispos. 1992. PMID: 1533542 Clinical Trial.
-
Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses.Antimicrob Agents Chemother. 1991 Dec;35(12):2551-7. doi: 10.1128/AAC.35.12.2551. Antimicrob Agents Chemother. 1991. PMID: 1839759 Free PMC article. Clinical Trial.
-
Pharmacokinetics and bioavailability of a new formulation of teicoplanin following intravenous and intramuscular administration to humans.J Pharm Sci. 1991 Jun;80(6):605-7. doi: 10.1002/jps.2600800621. J Pharm Sci. 1991. PMID: 1834827 Clinical Trial.
-
Clinical pharmacokinetics of teicoplanin.Clin Pharmacokinet. 1990 Mar;18(3):184-209. doi: 10.2165/00003088-199018030-00002. Clin Pharmacokinet. 1990. PMID: 2138946 Review.
Cited by
-
Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.Pharmacoeconomics. 1995 Apr;7(4):357-74. doi: 10.2165/00019053-199507040-00009. Pharmacoeconomics. 1995. PMID: 10155323 Review.
-
Clinical pharmacokinetics of teicoplanin.Clin Pharmacokinet. 2000 Sep;39(3):167-83. doi: 10.2165/00003088-200039030-00001. Clin Pharmacokinet. 2000. PMID: 11020133 Review.
-
Teicoplanin physiologically based pharmacokinetic modeling offers a quantitative assessment of a theoretical influence of serum albumin and renal function on its disposition.Eur J Clin Pharmacol. 2021 Aug;77(8):1157-1168. doi: 10.1007/s00228-021-03098-w. Epub 2021 Feb 1. Eur J Clin Pharmacol. 2021. PMID: 33527208
-
Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy.Eur J Clin Microbiol Infect Dis. 2019 Nov;38(11):2113-2120. doi: 10.1007/s10096-019-03652-6. Epub 2019 Aug 1. Eur J Clin Microbiol Infect Dis. 2019. PMID: 31372903
-
Population pharmacokinetic study of teicoplanin in severely neutropenic patients.Antimicrob Agents Chemother. 1996 May;40(5):1242-7. doi: 10.1128/AAC.40.5.1242. Antimicrob Agents Chemother. 1996. PMID: 8723474 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials